Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, October 16, 2026 at 4.00 PM IST to discuss the Company's unaudited financial results for the quarter and half year ended September 30, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has received an ESG rating of Crisil ESG 63 under the Strong category from Crisil ESG Ratings & Analytics Limited for Fiscal 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange regarding update on approval of Final Reminder cum Forfeiture Notice for payment of outstanding call money related to its Rights Issue.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has issued a reminder to shareholders holding physical shares to furnish their PAN, KYC details, bank account details, and nomination details as per SEBI's Master Circular. The company has dispatched the reminder letters to the shareholders and has made the prescribed forms available on its website.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange regarding the closure of the trading window due to the SEBI (Prohibition of Insider Trading) Regulations, 2015, effective from October 1, 2026, until 48 hours after the declaration of financial results for the quarter and half year ending September 30, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the exchange regarding the Voting Results and the Scrutinizer's report of the Ninth Annual General Meeting.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026, through video conferencing. The meeting was chaired by R. Ramakrishnan, and attended by various directors, management officials, and invitees. The financial and operational performance of the Company for Financial Year 2025-26 was presented by Sandeep Shashikantha Rao, Managing Director & CEO, and Sarat Kumar Asuri, CFO. The Auditor's Reports for the financial year ended March 31, 2026, did not contain any qualification, observation, or adverse remarks.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has received a Rectification Order from the Assistant Commissioner of Income Tax, Central Circle 3, Thane, rectifying the error in tax computation and dropping the tax demand of Rs. 161.92 Crores raised pursuant to the Demand Notice received on March 17, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange about the completion of dispatch of 9th AGM Notice and Annual report.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange about Business Responsibility and Sustainability Report for the financial year 2025-26.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of Ninth Annual General Meeting (AGM) scheduled to be held on September 18, 2026, to consider and adopt the Audited Standalone Financial Statements for the financial year ended March 31, 2026, and other business.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Stock Exchange regarding the Newspaper Publication with respect to the Ninth Annual General Meeting.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange regarding the conversion of partly paid-up Rights Equity Shares into fully paid-up equity shares in relation to the rights issue by the Company, upon receipt of the Call Monies, as applicable.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 2250 equity shares pursuant to exercise of ESOP options.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the exchange about the change in joining date/appointment date of Mr. Ajit Manocha as Chief Information Officer (CIO) and Senior Management Personnel (SMP) of the Company. The effective date of his appointment has been revised from August 10, 2026 to August 17, 2026 due to personal reasons.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has informed the Exchange about Transcript of Earnings conference call pertaining to financial results of the Company for the quarter ended June 30, 2026.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has published unaudited financial results for the quarter ended June 30, 2026, through a newspaper advertisement and on its website.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has submitted the Machine Readable copy of financial results for the quarter ended June 30, 2026, as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Solara Active Pharma Sciences Limited

Solara Active Pharma Sciences Limited has uploaded the audio recording of its Q1 FY27 earnings call, held on July 23, 2026, for the quarter ended June 30, 2026, on its website.